Accent Therapeutics
- Company typePrivate
- Founded2017
- HeadquartersLexington, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Accent Therapeutics firmographics
Firmographics- Name
- Accent Therapeutics
- Legal name
- ACCENT THERAPEUTICS
- Website
- https://accenttx.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Accent Therapeutics industry classification
Industry- Product category
- Precision Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
- akta.pro secondary industries
- Translational Medicine & Biomarkers (HLAIALAF), Oncology Pathways & Precision Medicine Decision Support (HLACAGAH), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)
Keywords
Where Accent Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Lexington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Accent Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Drug Development and Commercialization: Pre-revenue clinical-stage biopharma company developing small molecule cancer therapeutics. Revenue expected from future drug commercialization upon regulatory approval. The company retains full worldwide rights to its KIF18A program and DHX9 program.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Accent Therapeutics product offering
Product offeringCore offering
Accent Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision oncology drugs that exploit genomic and chromosomal instability in cancer cells. Its lead program ATX-295 is an oral KIF18A inhibitor in Phase 1/2 clinical trials for platinum-resistant ovarian cancer and squamous non-small cell lung cancer, with a partnership with AstraZeneca covering RNA-modifying protein targets and a preclinical program licensed to Boehringer Ingelheim.
Product overview
Accent Therapeutics is a clinical-stage biopharmaceutical company pioneering small molecule precision cancer therapies. The company's portfolio includes ATX-295, a potentially best-in-class KIF18A inhibitor currently in Phase 1/2 clinical trials for ovarian and lung cancers, and a licensed preclinical oncology program targeting ISG expression acquired by Boehringer Ingelheim. The company leverages expertise in genomic instability and RNA-modifying proteins to develop targeted cancer therapies.
Differentiator
Problem solved
Functional benefit
Products and services
- ATX-295 A potentially best-in-class oral small molecule inhibitor of KIF18A, a mitotic kinesin motor protein critical for cell division in tumors with chromosomal instability. ATX-295 induces rapid cell death in aneuploid cancer cells while leaving euploid (normal) cells unaffected, and is currently in Phase 1/2 clinical trials for high-grade serous ovarian cancer and squamous non-small cell lung cancer. It is being developed for oncology indications with high unmet need where selective tumor cell killing can be achieved.
- ATX-559 A first-in-class oral small molecule inhibitor of DHX9, an RNA and DNA/RNA helicase target active in tumors with high replication stress. ATX-559 was being studied in a Phase 1/2 clinical trial for solid tumors including BRCA1/2-deficient breast cancer and MSI-H/dMMR tumors. The program was terminated due to adverse event profile and Accent is evaluating strategic options.
- Preclinical ISG Expression Program A novel preclinical small molecule oncology program targeting tumors with high interferon-stimulated gene (ISG) expression, designed to stimulate antitumor immunity. The program was licensed to Boehringer Ingelheim, which assumed global responsibility for research, development, manufacturing, and commercialization.
Quantifiable outcome
- 60-70% of ovarian cancer patients will eventually develop platinum resistance
- +1 more outcomes
Companies that use Accent Therapeutics
Customer profileSegments4 records
Ideal customer profiles2 records
Accent Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
Accent Therapeutics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and flagship.
- Boehringer IngelheimcoreBoehringer Ingelheim has entered into an agreement to acquire from Accent a novel preclinical small molecule program with an approach for tumors characterized by high interferon-stimulated gene (ISG) expression. Boehringer Ingelheim has assumed global responsibility for the program's research, development, manufacturing, and commercialization, advancing it toward clinical evaluation.
- AstraZenecaflagshipAccent and AstraZeneca have a transformational partnership to discover, develop and commercialize certain novel therapeutics targeting RNA-modifying proteins (RMPs) for the treatment of cancer. The collaboration seeks to rapidly advance and achieve the rich therapeutic potential of the exciting programs under partnership by combining AstraZeneca's proven track record in bringing forward novel oncology medicines with Accent's industry-leading expertise in the biology, target identification and drug discovery of RMP-targeting therapies.
- InocrascoreAccent Therapeutics is using Inocras' CancerVision and MRDVision platforms in a Phase 1/2 clinical study of ATX-295. The platforms provide detailed tumor genomic profiling and ultra-sensitive monitoring of treatment response, supporting drug development and clinical decision-making.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Accent Therapeutics competitors and assessment
Company assessmentDirect peers
- Tango Therapeutics: Clinical-stage precision oncology company developing synthetic lethality-based small molecule therapies. Directly comparable to Accent in targeting novel cancer biology vulnerabilities in genomically defined patient populations.
- Repare Therapeutics: Precision oncology company developing synthetic lethality-based small molecule drugs. Similar clinical stage, similar focus on novel cancer targets and biomarker-driven patient selection strategies.
- Black Diamond Therapeutics: Clinical-stage precision oncology company developing small molecule targeted therapies across multiple tumor types. Comparable in targeting novel oncogenic drivers and genomically defined patient populations.
- Relay Therapeutics: Clinical-stage precision oncology company using motion-based drug design to develop small molecule therapies. Comparable clinical stage with similar strategy of targeting novel cancer biology with biomarker-driven development.
- Erasca: Clinical-stage precision oncology company focused on the RAS/MAPK pathway with multiple small molecule drug candidates. Similar clinical-stage profile, biomarker-driven development approach, and oncology focus.
- Foghorn Therapeutics: Clinical-stage biotech developing small molecule drugs targeting chromatin biology in cancer. Comparable in developing small molecule precision oncology therapies targeting novel cancer biology mechanisms.
- HotSpot Therapeutics: Clinical-stage precision oncology company developing small molecule allosteric modulators. Comparable in targeting previously undrugged cancer biology with novel small molecule approaches.
Emerging players
- Kymera Therapeutics: Clinical-stage biotech developing small molecule targeted protein degraders with multiple oncology programs. Overlaps with Accent in precision oncology and novel target biology, though focused on degradation rather than inhibition.
Broad incumbents
- AstraZeneca: Global biopharmaceutical company with a major oncology franchise and an existing partnership with Accent on RNA-modifying proteins. Relevant as a broad incumbent in precision oncology and as Accent's strategic partner.
- Bristol-Myers Squibb: Global biopharmaceutical company with a leading oncology franchise and an investor in Accent Therapeutics. Comparable as a broad incumbent in oncology drug development and a strategic investor relationship.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Accent Therapeutics social profiles
Digital presenceAccent Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Accent Therapeutics leadership team
Management profileNumber of profiles
Profiles14 records
Accent Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Accent Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Accent Therapeutics
What does Accent Therapeutics do?
Accent Therapeutics is a clinical-stage biopharmaceutical company developing small molecule precision oncology drugs that exploit genomic and chromosomal instability in cancer cells. Its lead program ATX-295 is an oral KIF18A inhibitor in Phase 1/2 clinical trials for platinum-resistant ovarian cancer and squamous non-small cell lung cancer, with a partnership with AstraZeneca covering RNA-modifying protein targets and a preclinical program licensed to Boehringer Ingelheim.
Is Accent Therapeutics a public or private company?
Accent Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Accent Therapeutics founded?
Accent Therapeutics was founded in 2017. It employs 11 to 50 people.
Where is Accent Therapeutics based?
Accent Therapeutics is headquartered in Lexington, United States, in the North America region.
How does Accent Therapeutics make money?
One revenue line is on record: drug Development and Commercialization.
Who are Accent Therapeutics's main competitors?
Direct peers on record are Tango Therapeutics, Repare Therapeutics, Black Diamond Therapeutics, Relay Therapeutics, Erasca, Foghorn Therapeutics and HotSpot Therapeutics. Kymera Therapeutics is listed as an emerging player. Broad incumbents are AstraZeneca and Bristol-Myers Squibb.
Does Accent Therapeutics have an API?
No public API is recorded for Accent Therapeutics.
What industry is Accent Therapeutics in?
Accent Therapeutics's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 541714 and its SIC code is 2834.